skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 492,390  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Refined by: resource type: Articles remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Single-cell spatial landscapes of the lung tumour immune microenvironment
Single-cell spatial landscapes of the lung tumour immune microenvironment
Material Type:
Article 		Add to My Research

Single-cell spatial landscapes of the lung tumour immune microenvironment

Nature (London), 2023-02, Vol.614 (7948), p.548-554 [Peer Reviewed Journal]

2023. The Author(s). ;Copyright Nature Publishing Group Feb 16, 2023 ;The Author(s) 2023 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-022-05672-3 ;PMID: 36725934

Full text available

Citations Cited by
2
Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial
Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial
Material Type:
Article 		Add to My Research

Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.1732-1742 [Peer Reviewed Journal]

2019 ;Copyright © 2019 by the International Association for the Study of Lung Cancer ;Published by Elsevier Inc. ;ISSN: 1556-0864 ;EISSN: 1556-1380 ;DOI: 10.1016/j.jtho.2019.05.044 ;PMID: 31260833

Full text available

Citations Cited by
3
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Material Type:
Article 		Add to My Research

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Journal of clinical oncology, 2019-02, Vol.37 (4), p.278-285 [Peer Reviewed Journal]

2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.18.01585 ;PMID: 30550363

Full text available

Citations Cited by
4
miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells
miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells
Material Type:
Article 		Add to My Research

miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells

PloS one, 2013-03, Vol.8 (3), p.e60317-e60317 [Peer Reviewed Journal]

COPYRIGHT 2013 Public Library of Science ;2013 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Chen et al 2013 Chen et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0060317 ;PMID: 23555954

Full text available

Citations Cited by
5
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Material Type:
Article 		Add to My Research

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Nature communications, 2015-03, Vol.6 (1), p.6377-6377, Article 6377 [Peer Reviewed Journal]

Copyright Nature Publishing Group Mar 2015 ;Copyright © 2015, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/ncomms7377 ;PMID: 25758528

Full text available

Citations Cited by
6
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8 + T cell exhaustion
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8 + T cell exhaustion
Material Type:
Article 		Add to My Research

Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8 + T cell exhaustion

Nature communications, 2020-09, Vol.11 (1), p.4520-4520, Article 4520 [Peer Reviewed Journal]

The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-020-18298-8 ;PMID: 32908154

Full text available

Citations Cited by
7
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Material Type:
Article 		Add to My Research

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2027071 ;PMID: 32955177

Full text available

Citations Cited by
8
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Material Type:
Article 		Add to My Research

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1910231 ;PMID: 31562796

Full text available

Citations Cited by
9
Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancer
Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancer
Material Type:
Article 		Add to My Research

Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancer

Cochrane database of systematic reviews, 2015-03, Vol.2015 (3), p.CD011430-CD011430 [Peer Reviewed Journal]

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;ISSN: 1469-493X ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD011430 ;PMID: 25730344

Full text available

Citations Cited by
10
Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer
Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer
Material Type:
Article 		Add to My Research

Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer

PloS one, 2012-04, Vol.7 (4), p.e35065-e35065 [Peer Reviewed Journal]

COPYRIGHT 2012 Public Library of Science ;COPYRIGHT 2012 Public Library of Science ;2012 Lv et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Lv et al. 2012 ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0035065 ;PMID: 22493729

Full text available

Citations Cited by
11
Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Material Type:
Article 		Add to My Research

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2022-01, Vol.386 (3), p.241-251 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2112431 ;PMID: 34534430

Full text available

Citations Cited by
12
Progress and prospects of early detection in lung cancer
Progress and prospects of early detection in lung cancer
Material Type:
Article 		Add to My Research

Progress and prospects of early detection in lung cancer

Open biology, 2017-09, Vol.7 (9), p.170070 [Peer Reviewed Journal]

2017 The Authors. ;2017 The Authors. 2017 ;ISSN: 2046-2441 ;EISSN: 2046-2441 ;DOI: 10.1098/rsob.170070 ;PMID: 28878044

Full text available

Citations Cited by
13
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Material Type:
Article 		Add to My Research

Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Nature (London), 2023-04, Vol.616 (7957), p.563-573 [Peer Reviewed Journal]

2023. The Author(s). ;Copyright Nature Publishing Group Apr 20, 2023 ;The Author(s) 2023 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-023-05771-9 ;PMID: 37046094

Full text available

Citations Cited by
14
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Material Type:
Article 		Add to My Research

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

The lancet oncology, 2018-01, Vol.19 (1), p.139-148 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Jan 1, 2018 ;2018. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30729-5 ;PMID: 29174310

Full text available

Citations Cited by
15
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Material Type:
Article 		Add to My Research

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1655-1669 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30634-5 ;PMID: 31591063

Full text available

Citations Cited by
16
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Material Type:
Article 		Add to My Research

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

PloS one, 2015-06, Vol.10 (6), p.e0130142-e0130142 [Peer Reviewed Journal]

COPYRIGHT 2015 Public Library of Science ;COPYRIGHT 2015 Public Library of Science ;2015 Carbognin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2015 Carbognin et al 2015 Carbognin et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0130142 ;PMID: 26086854

Full text available

Citations Cited by
17
The evolution of lung cancer and impact of subclonal selection in TRACERx
The evolution of lung cancer and impact of subclonal selection in TRACERx
Material Type:
Article 		Add to My Research

The evolution of lung cancer and impact of subclonal selection in TRACERx

Nature (London), 2023-04, Vol.616 (7957), p.525-533 [Peer Reviewed Journal]

2023. The Author(s). ;Copyright Nature Publishing Group Apr 20, 2023 ;The Author(s) 2023 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-023-05783-5 ;PMID: 37046096

Full text available

Citations Cited by
18
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Material Type:
Article 		Add to My Research

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Nature communications, 2019-04, Vol.10 (1), p.1486-17, Article 1486 [Peer Reviewed Journal]

This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;The Author(s) 2019 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-019-09415-3 ;PMID: 30940805

Full text available

Citations Cited by
19
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Material Type:
Article 		Add to My Research

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-11, Vol.377 (20), p.1919-1929 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1709937 ;PMID: 28885881

Full text available

Citations Cited by
20
Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer
Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer
Material Type:
Article 		Add to My Research

Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer

PloS one, 2021-12, Vol.16 (12), p.e0260988-e0260988 [Peer Reviewed Journal]

COPYRIGHT 2021 Public Library of Science ;2021 Rice, Belani. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Rice, Belani 2021 Rice, Belani ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0260988 ;PMID: 34855926

Full text available

Citations Cited by

Results 1 - 20 of 492,390  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (439,329)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1958  (8,257)
  2. 1958 To 1973  (13,818)
  3. 1974 To 1989  (39,026)
  4. 1990 To 2006  (103,514)
  5. After 2006  (327,971)
  6. More options open sub menu

Subject 

  1. Science & Technology  (369,889)
  2. Life Sciences & Biomedicine  (343,908)
  3. Humans  (269,982)
  4. Male  (149,432)
  5. Female  (138,972)
  6. Animals  (109,406)
  7. Lung Cancer  (104,327)
  8. Middle Aged  (87,762)
  9. Oncology  (82,908)
  10. Biological And Medical Sciences  (75,654)
  11. Respiratory System  (71,474)
  12. Aged  (70,222)
  13. Adult  (68,481)
  14. Lungs  (66,953)
  15. Medical Sciences  (65,578)
  16. Mice  (51,721)
  17. Lung Diseases  (51,220)
  18. Patients  (45,270)
  19. Lung Neoplasms - Pathology  (44,557)
  20. General & Internal Medicine  (44,303)
  21. More options open sub menu

Language 

  1. English  (473,400)
  2. Japanese  (57,891)
  3. German  (4,882)
  4. Chinese  (4,697)
  5. French  (3,909)
  6. Portuguese  (2,798)
  7. Spanish  (2,789)
  8. Korean  (1,420)
  9. Russian  (803)
  10. Turkish  (782)
  11. Polish  (573)
  12. Norwegian  (286)
  13. Italian  (246)
  14. Swedish  (156)
  15. Persian  (125)
  16. Croatian  (78)
  17. Serbian  (54)
  18. Ukrainian  (53)
  19. Czech  (42)
  20. Icelandic  (38)
  21. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait